Pliant Therapeutics (PLRX)
(Delayed Data from NSDQ)
$15.20 USD
+0.53 (3.61%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $15.27 +0.07 (0.46%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.20 USD
+0.53 (3.61%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $15.27 +0.07 (0.46%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
Pliant Therapeutics, Inc. (PLRX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose
by Zacks Equity Research
Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.
How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 127%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Pliant Therapeutics, Inc. (PLRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study
by Zacks Equity Research
Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study
by Zacks Equity Research
Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.
bluebird (BLUE) Up 101% in the Past Three Months: Here's Why
by Zacks Equity Research
bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.
Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.
How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 106%
by Zacks Equity Research
The mean of analysts' price targets for Pliant Therapeutics, Inc. (PLRX) points to a 105.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The Zacks Analyst Blog Highlights Absci Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics
by Zacks Equity Research
Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
by Kinjel Shah
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 0% and 269.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amicus (FOLD) Q2 Earnings Beat, Galafold Sales Miss Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) posts a narrower-than-expected loss for the second quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics
by Zacks Equity Research
Amarin's (AMRN) Vazkepa sales decline year over year amid rising generic competition and COVID-related disruptions during the second quarter. The company's stock witnesses a decline on Aug 3.
Repligen (RGEN) Q2 Earnings and Sales Beat Estimates, Stock Up
by Zacks Equity Research
Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022
Analysts Estimate Kymera Therapeutics, Inc. (KYMR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Kymera Therapeutics, Inc. (KYMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 142%
by Zacks Equity Research
The consensus price target hints at a 142.4% upside potential for Pliant Therapeutics, Inc. (PLRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Pliant Therapeutics (PLRX) Up on Positive Data From Lung Disease Study
by Zacks Equity Research
Pliant Therapeutics (PLRX) reports favorable data from a mid-stage study, which supports the potential of PLN-74809, its experimental drug candidate for treating IPF.
Pliant Therapeutics, Inc. (PLRX) Stock Jumps 159%: Will It Continue to Soar?
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -1.30% and 12.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -5.71% and 21.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 10.53% and 45.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Pliant Therapeutics, Inc. (PLRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Pliant Therapeutics, Inc. (PLRX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -5.63% and -35.60%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?